Compare · SLNO vs VAR
SLNO vs VAR
Side-by-side comparison of Soleno Therapeutics Inc. (SLNO) and Varian Medical Systems, Inc. (VAR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLNO and VAR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO carries a market cap of $2.76B.
- SLNO has hit the wire 39 times in the past 4 weeks while VAR has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for VAR).
- Company
- Soleno Therapeutics Inc.
- Varian Medical Systems, Inc.
- Price
- $53.02+0.08%
- -
- Market cap
- $2.76B
- -
- 1M return
- +0.76%
- -
- 1Y return
- -31.78%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- n/a
- News (4w)
- 39
- 0
- Recent ratings
- 12
- 0
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest VAR
- Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian
- Varian and Icon Group Partner to Extend Commitment to Global Cancer Care
- SEC Form 15-12B filed by Varian Medical Systems, Inc.
- SEC Form 4: Balser Jeffrey R. returned 2,824 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BUTEL JEAN LUC returned 4,048 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: DUGAN REGINA E returned 12,396 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: ECKERT R ANDREW gifted 447 units of Common Stock and returned 13,826 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BRUNER JUDY returned 6,779 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: ILLINGWORTH DAVID J returned 15,369 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: WILSON DOW R returned 39,231 units of Common Stock to the company and gifted 65,558 units of Common Stock, decreasing direct ownership by 100% to 0 units